COLUMBIA, Md. - Marylandian -- Precision Antibody, a leader in custom monoclonal antibody development, announces its participation in the Targeted Therapies Licensing & Partnering Summit Asia 2026, taking place February 26–27, 2026, in Meguro-ku, Tokyo, Japan.

Precision Antibody will attend the partnering-focused meeting alongside A&G Pharmaceutical, Inc., engaging with biopharmaceutical companies, investors, and research leaders to explore strategic collaborations in targeted therapies and antibody-based drug development.

The Targeted Therapies Licensing & Partnering Summit Asia is a premier event designed to facilitate high-value business development discussions, licensing opportunities, and cross-border partnerships within oncology and precision medicine. The summit provides a dedicated platform for companies advancing innovative therapeutic assets to connect with potential partners across Asia and globally.

More on Marylandian

• Evermore Bliss Launches AI Wedding Speech Writer to Help Users Create Personalized, Heartfelt Toasts
• Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
• Leading PEO INFINITI HR Announces Industry Veteran, Javier Ramirez, as New COO
• Spring Into Your New Home at Heritage at South Brunswick
• ULiveUSA Launches New "Moment Marketing" System Using Videos to Help Local Businesses Get More Customers

Precision Antibody brings to the meeting its extensive expertise in custom monoclonal antibody development, including fully human antibody generation and biomarker-focused antibody solutions that support therapeutic and translational research initiatives.

"Partnering meetings like this play a critical role in accelerating innovation," said Dr. Serrero. "We look forward to engaging with potential collaborators in Tokyo and exploring opportunities to advance targeted therapy programs through strategic partnerships."

As biomarker antibody specialists, Precision Antibody has established a strong track record in developing high-quality, high-affinity monoclonal antibodies for oncology research. The company is also a proud contributor to the National Cancer Institute's Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies widely used in cancer biomarker research.

More on Marylandian

• UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
• Pages of Purpose LLC Brings Cash Home Buying Solutions to Maryland Homeowners Others Won't Help
• HarryPotterObamaSonic10Inu (Ticker: BITCOIN) Is the Best Cryptocurrency in Global History
• Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
• GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows

Through its collaboration-driven approach and commitment to scientific excellence, Precision Antibody continues to support biopharma partners in accelerating the discovery and development of next-generation targeted therapeutics.

Attendees of the Targeted Therapies Licensing & Partnering Summit Asia 2026 are invited to connect with representatives from Precision Antibody and A&G Pharmaceutical to discuss licensing opportunities, co-development partnerships, and strategic collaborations.

Event Details:

Targeted Therapies Licensing & Partnering Summit Asia 2026
Dates: February 26–27, 2026
Location: Meguro-ku, Tokyo, Japan
Event Website: https://targeted-therapies-asia.com/